ProMIS Neurosciences Inc. (PMN): Price to Sales

ProMIS Neurosciences focuses on developing targeted antibodies against Alzheimer's disease using computational biology, which minimizes tissue risks. The company is supported by colossal demand for safe therapies and a scalable profit model driven by patents. The company's P/S ratio visualizes the business value dynamics, where determines the current status of the parameter relative to market expectations for R&D investments.

ProMIS Neurosciences (PMN) Market Cap to Revenue: for the period 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for ProMIS Neurosciences (PMN)

- current price and projected stock value:

Price Chart promisneurosciences.com|PMN - Price Target Chart

- stock exchange capitalization data:

Market Value ProMIS|PMN - Enterprise Value

- shareholders' equity book value data:

Book Value of One Share ProMIS Neurosciences|PMN - Company Net Assets|Market-to-Book Ratio promisneurosciences.com|PMN - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and market multiples details:

PMN - Company Net Income|Company Profit Forecast ProMIS Neurosciences|PMN - Price to Earnings Ratio|Future Price to Earnings Multiple promisneurosciences.com|PMN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation ProMIS|PMN - Operating profit EBITDA|Net earnings per one share for the last twelve months ProMIS Neurosciences|PMN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth promisneurosciences.com|PMN - Earnings per share growth in current year|Expected earnings per share trend next year ProMIS Neurosciences

- sales revenue and business income indicators:

PMN - Company Revenue|Company Expected Sales Volume promisneurosciences.com|PMN - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio ProMIS

Fundamental company analysis:PMN - ProMIS Neurosciences Inc.

Flagship merchandise of ProMIS Neurosciences, Inc.

The historical P/S trend reflects market expectations for the expansion of ProMIS Neurosciences (PMN) within the Alzheimer's disease therapy segment. This multiple compares current market capitalization to annual revenue, determining the degree of business overvaluation. The price-to-sales ratio allows for an assessment of the premium investors are willing to pay for the potential of innovative drugs. Analyzing this indicator helps avoid overpaying at the peak of demand within the emerging biotechnology sector.

Competitors of ProMIS Neurosciences

Price-to-Revenue Ratio JAZZ (jazzpharma.com)|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc (PTCT) - Price to Sales|Scholar Rock Corp - P/S Multiple|Price-to-Revenue Multiple Centessa Corp (CNTA)|DYN (Dyne Therapeutics, Inc.) - Market Cap to Revenue|Price to Sales edgewisetx.com (EWTX)|Price-to-Revenue Ratio Rapport Therapeutics|Alumis Inc - Price-to-Sales Ratio|Price-to-Revenue Ratio Kempharm (ZVRA)|CTNM (Contineum Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Larimar Therapeutics LRMR|Capricor Therapeutics Inc. (CAPR) - Price to Sales|TRDA - Price-to-Revenue Ratio|Channel Therapeutics Inc. (PTHS) - Market Cap to Revenue|MNOV: P/S Multiple|SER - Price-to-Revenue Coefficient|Price-to-Revenue Ratio BioXcel Therapeutics|Apimeds (APUS) - Price-to-Revenue Coefficient|Market Cap to Revenue AEON (AEON Biopharma)|NLSP (nlspharma.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Bionomics BNOX|HUGE: Market Cap to Revenue Ratio|Reata Pharmaceuticals - P/S Multiple